Human CD8 and CD4 T cell epitopes of epithelial cancer antigens

被引:16
|
作者
Sato, N
Nabeta, Y
Kondo, H
Sahara, H
Hirohashi, Y
Kashiwagi, K
Kanaseki, T
Sato, Y
Rong, S
Hirai, I
Kamiguchi, K
Tamura, Y
Matsuura, A
Takahashi, S
Torigoe, T
Ikeda, H
机构
[1] Sapporo Med Univ, Sch Med, Dept Pathol, Chuo Ku, Sapporo, Hokkaido 0608556, Japan
[2] Keio Univ, Sch Med, Inst Adv Med Res, Div Cellular Signaling,Shinjuku Ku, Tokyo 1608582, Japan
关键词
antigenic peptides; epithelial cancer; immunotherapy;
D O I
10.1007/PL00014057
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent human tumor immunology research has identified several genes coding immunogenic peptides recognized by CD8 cytotoxic T lymphocytes (CTLs) in melanoma tumors. Very recently, CD4 T cell antigenic epitopes were also determined in certain melanoma tumors. The use of these peptides in conjunction with human immunotherapy could prove to be of great benefit. However, such peptides in clinically common tumors of epithelial cell origin, such as of the stomach, colon, lung, etc., have not yet been determined extensively. We describe for the first time an HLA-A31 (A*31012)-restricted natural antigenic peptide recognized by the CD8 CTL TcHST-2 of gastric signet ring cell carcinoma cell line HST-2. We also identified the HLA-DRB1*08032-restricted peptide recognized by the CD4 T cell line TcOSC-20 of squamous cell carcinoma OSC-20 derived from the oral cavity. The antigenic peptide of HST-2, designated F4.2, is composed of 10 amino acid residues with two anchor motif residues necessary for binding to HLA-A31 molecules. The synthetic F4.2 peptide enhanced the reactivity of TcHST-2 against HST-2 cells. Furthermore, introduction of an expression minigene coding F4.2 peptide to HLA-A31(+) cells conferred cytotoxic susceptibility to TcHST-2 on the cells. Some stomach cancer lines into which the HLA-A31 gene had been introduced, such as MKN28-A31-2, were lysed by TcHST-2, suggesting the presence of F4.2 peptide in at least some HLA-A31(+) stomach cancers. Furthermore, F4.2 peptide induced an F4.2 peptide-specific CTL response in at least 30-40% of HLA-A31(+) peripheral blood lymphocytes from gastric cancer patients, suggesting that F4.2 peptide could be used as a cancer vaccine for gastric tumors. The natural antigenic peptide of OSC-20 was also determined using acid extraction and biochemical separation and by mass spectrometry. Consequently, OSC-20 peptide was designated as the 6-1-5 peptide, an HLA-DRB1*08032-restricted 16-mer peptide with two possible anchor motifs. It has an amino acid sequence identical to that of human alpha-enolase, suggesting that it was derived from the processed parental alpha-enolase protein. We are presently attempting to determine the genes that code tumor rejection antigens recognized by HLA-A24- and A26-restricted T cells, including those of pulmonary and pancreatic carcinomas. The search for these antigenic peptides may lead to the identification of immunogenic peptide antigens that would be suitable for clinical use in commonly occurring epithelial cancers.
引用
收藏
页码:S86 / S90
页数:5
相关论文
共 50 条
  • [41] Activation of CD4 and CD8 T cell receptors and regulatory T cells in response to human proteins
    Arneth, Borros M.
    PEERJ, 2018, 6
  • [42] CD4 T cell help for a more potent CD8 T cell response against hepatocyte-expressed antigens
    English, K.
    Sierro, F.
    Tay, S. S.
    Wood, N. A. W.
    McGuffog, C.
    McCaughan, G. W.
    Bowen, D. G.
    Wong, Y. C.
    Bertolino, P.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 977 - 978
  • [43] Human Mycobacterium tuberculosis CD8 T Cell Antigens/Epitopes Identified by a Proteomic Peptide Library
    Lewinsohn, David M.
    Swarbrick, Gwendolyn M.
    Cansler, Meghan E.
    Null, Megan D.
    Rajaraman, Veena
    Frieder, Marisa M.
    Sherman, David R.
    McWeeney, Shannon
    Lewinsohn, Deborah A.
    PLOS ONE, 2013, 8 (06):
  • [44] Synergistic CD4 and CD8 T Cell Receptor Platform for Stem Cell Based Therapy for Cancer
    Koya, Richard C.
    Chodon, Thinle
    Matsueda, Satoko
    Matsuzaki, Junko
    Tsuji, Takemasa
    Odunsi, Kunle
    MOLECULAR THERAPY, 2017, 25 (05) : 252 - 252
  • [45] CD4, CD8 AND THE ROLE OF CD45 IN T-CELL ACTIVATION
    LEDBETTER, JA
    DEANS, JP
    ARUFFO, A
    GROSMAIRE, LS
    KANNER, SB
    BOLEN, JB
    SCHIEVEN, GL
    CURRENT OPINION IN IMMUNOLOGY, 1993, 5 (03) : 334 - 340
  • [46] Positive selection of CD4(+) and CD8(+) T cells
    Guidos, CJ
    CURRENT OPINION IN IMMUNOLOGY, 1996, 8 (02) : 225 - 232
  • [47] Conversion of the CD8 lineage to CD4 T cells
    Guzman, Maria P.
    Chen, Zhibin
    ONCOTARGET, 2015, 6 (25) : 20748 - 20749
  • [48] CD4 and CD8 t-lymphocyte recognition
    Robert F. Donnell
    Current Urology Reports, 2005, 6 (4) : 280 - 280
  • [49] CD4(+), CD8(+) AND CD4(-) CD8 T-CELL-SUBSETS CAN CONFER PROTECTION AGAINST LEISHMANIA-M-MEXICANA INFECTION
    LEZAMADAVILA, CM
    GALLAGHER, G
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 1995, 90 (01): : 51 - 58
  • [50] THE ASSOCIATION OF P56LCK WITH THE CD4/CD8 ANTIGENS - IMPLICATIONS FOR T-CELL FUNCTION
    RUDD, CE
    SCHLOSSMAN, SF
    PROGRESS IN IMMUNOLOGY, VOL 7, 1989, : 683 - 686